Public Summary

Summary for ARTG Entry:	302620 Lymphodran Plus
ARTG entry for	Medicine Listed
Sponsor	Bio Concepts Pty Ltd
Postal Address	PO Box 190, Banyo, Brisbane, QLD, 4014 Australia
ARTG Start Date	4/05/2018
Product Category	Medicine
Status	Active
Approval Area	Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Lymphodran Plus

Product Type	Single Medicine Product	**Effective Date**	17/02/2020

Permitted Indications

Antioxidant/Reduce free radicals formed in the body

Maintain/support collagen formation

Maintain/support general health and wellbeing

Aid/assist/helps connective tissue production/formation

Maintain/support cardiovascular system health

Maintain/support blood capillary health

Maintain/support immune system health

Maintain/support healthy immune system function

Helps prevent dietary (state vitamin/mineral/nutrient) deficiency in healthy individuals

Aid/assist/helps synthesis of neurotransmitters

Maintain/support wound healing in healthy individuals

Indication Requirements

Product presentation must not imply or refer to serious immunological diseases.

Label statement: If symptoms persist, talk to your health professional.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to serious cardiovascular conditions.

Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.

If symptoms persist, seek the advice of a healthcare professional.

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule

Components

1 . Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

ascorbic acid	**50 mg**
bromelains	**5.6 million PU**
quercetin dihydrate	**526.32 mg**
Equivalent: quercetin	500 mg
rutoside	**400 mg**

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate
Carnauba Wax
crospovidone
hypromellose
macrogol 400
magnesium stearate
maltodextrin
microcrystalline cellulose
povidone
silicon dioxide